Official ESCRS | European Society of Cataract & Refractive Surgeons
Vienna 2018 Delegate Registration Programme Exhibition Virtual Exhibition Satellites 2018 Survey


escrs app advert


Search Title by author or title

Transepithelial photorefractive keratectomy in treatment of hyperopia

Poster Details

First Author: H.Hasani IRAN

Co Author(s):                        

Abstract Details


To evaluate the results of transepithelial photorefractive keratectomy (T-PRK) procedure in the treatment of hyperopia.


Bina Eye Hospital


In this retrospective case series study, 22 eyes of 11 patients were enrolled, who underwent Transepithelial Photorefractive Keratectomy (T-PRK) with mitomycin-C (MMC) for treatment of hyperopia using Amaris 500-Hz excimer laser (SCHWIND eye-tech solutions GmbH, Germany). After treatment, the efficacy, safety and complications of treatment were assessed at 1, 3 and 6 months postoperatively. Main outcome measures were visual acuity, manifest refractive spherical equivalent (MRSE) and complications.


The preoperative mean UDCVA 0.63 ± 0.05 logMAR improved to 0.19 ± 0.04 (P < .0001), 6 months postoperatively. 64.2% of the treated eyes gained an uncorrected distance visual acuity of 20/25 or better. Postoperative best corrected visual acuity (BCVA) of unchanged or gained ≥1 lines and postoperative BCVA of lost ≥2 lines were 86.3% (19 eyes) and 4.5% (1 eye), respectively. The mean MRSE was +0.45 D (-0.25 to 0.65 D) and the percentage of MRSE of within ±0.50 D was 95.4% (21 eyes). Four eyes (18.1%) lost one line of preoperative corrected distance visual acuity (CDVA).


The study showed that T-PRK with MMC is an effective and safe treatment for hyperopia correction. The incidence of corneal haze was reasonable.

Financial Disclosure:


Back to Poster listing